logo

Edgewise Therapeutics, Inc. (EWTX)



Trade EWTX now with
  Date
  Headline
6/20/2022 8:10:08 AM Edgewise Reports Positive Interim Results From ARCH Open Label Study Of EDG-5506 In Becker Muscular Dystrophy
5/11/2022 8:11:22 AM Edgewise Therapeutics Reports Q1 Net Loss Of $14.7 Mln Or $0.30/shr
2/24/2022 8:12:12 AM Edgewise Therapeutics FY Net Loss $42.8 Mln Or $1.14/shr Vs Loss Of $17.1 Mln Or $23.17/Shr Last Year
1/5/2022 8:25:00 AM Edgewise Announces Positive Results From EDG-5506 Phase 1b Trial In Adults With Becker Muscular Dystroph
11/10/2021 8:18:48 AM Edgewise Therapeutics Q3 Net Loss $12.9 Mln Or $0.26/shr Vs. Loss $3.6 Mln Prior Year
8/16/2021 9:05:25 AM Edgewise Receives FDA Fast Track Designation For EDG-5506 For Treatment Of Individuals With Becker Muscular Dystrophy
8/9/2021 9:09:38 AM Edgewise Therapeutics Q2 Loss Widens To $10.4 Mln Or $0.21/shr From $4.0 Mln Prior Year
5/4/2021 9:40:59 AM Edgewise Announces Publication Of Cross-sectional, retrospective Study On Duchenne Muscular Dystrophy
4/27/2021 9:03:56 AM Edgewise Therapeutics Appoints Joanne Donovan As Chief Medical Officer